Dr Falchi on the Use of Glofitamab in R/R LBCL

Lorenzo Falchi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of glofitamab-gxbm (Columvi) monotherapy in patients with relapsed/refractory large B-cell lymphoma (LBCL).

At the 2023 ASCO Annual Meeting, Falchi and colleagues presented data on the extended follow-up and landmark analyses from the pivotal phase 1/2 NP30179 trial (NCT03075696) evaluating the agent in this patient population. Notably, previously reported data from the study supported the FDA’s decision to grant accelerated approval to glofitamab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy, in June 2023.

Updated data presented at the 2023 ASCO Annual Meeting showed that responses were consistent with previous findings, Falchi begins. The overall response rate (ORR) was 52% (95% CI, 43.%-59.7%), and the complete response (CR) rate was 40% (95% CI, 32.2%-48.2%). This analysis was conducted at a median follow-up of 21.2 months for the entire population, and among patients who achieved a CR, 70% who reached 18 months of follow-up remained in remission, he explains.

Among patients who had a CR, 16 discontinued treatment due to progressive disease (n = 6), death (n = 4), new anti-lymphoma therapy (n = 2), lost to follow-up (n = 2), physician decision (n = 1), and patient withdrawal (n = 1). In patients who achieved a CR at end of treatment, the 12-month progression-free survival and overall survival rates were 80% and 92%, respectively.

These data suggest that if patients achieve a response to treatment with fixed-duration therapy, their likelihood of staying alive and progression-free at relatively long-term follow-up is quite high, Falchi expands. Investigators are seeing patients not relapsing for an extended period of time after the end of therapy, he concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.